1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Wesana Health Holdings Inc.
  6. News
  7. Summary
    WESA   CA95081C1059

WESANA HEALTH HOLDINGS INC.

(WESA)
  Report
Delayed CANADIAN NATIONAL STOCK EXCHANGE  -  03:02 2022-08-17 pm EDT
0.1750 CAD   +2.94%
06/08WESANA HEALTH CEO DANIEL CARCILLO TO KEYNOTE CHARLES RIVER SYMPOSIUM : Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies
AQ
05/31Wesana Announces First Quarter 2022 Financial Results
AQ
05/31Wesana Health Holdings Inc. Announces Resignation of Chad Bronstein as Executive Chairman
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

06/08/2022 | 09:47am EDT

CHICAGO and TORONTO, June 08, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to confirm CEO Daniel Carcillo will be keynoting the upcoming Charles River Symposium, “Re-imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies.”

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe, accelerate their research and drug development efforts.

Mr. Carcillo’s keynote, “From Advocate to Executive: How my patient experience influences my work as CEO,will cover his personal experience with psychedelic treatments and the inspiration that led him to found and lead Wesana. He will explore how he transformed himself from patient to advocate, to an inspiring leader.

  • Mr. Carcillo’s talk will begin at 9:10AM Pacific time on Thursday, June 9, 2022
  • Immediately following his keynote, Mateusz Dudek, PhD of Charles River will present “Reverse Engineering Discovery: A Collaborative Pathway to Preclinical Assessment of Daniel Carcillo's Experience”

Event Overview

The mental health epidemic, including substance use and addiction, is a global issue. The crises began long before the COVID-19 pandemic, but two years of work? loss, stress, isolation, and treatment disruption has only exacerbated the number of people struggling with their mental health. Innovations in the range of medicines currently used in conjunction with psychotherapy have had little to no progress over the last two decades. The use of psychedelic therapy has changed this paradigm. With increased preclinical research and clinical trials illustrating the beneficial effects of first-generation psychedelics, a wave of second-generation therapeutics is now emerging. This event will highlight progress in both areas of translational research and provide a panel discussion on the trials and tribulations of developing these therapies for commercialization. To attend this hybrid event virtually or in person, visit: https://bit.ly/3tZuibl

About Wesana Health

Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at www.wesanahealth.com.

Investor Relations:
Keenan Gentry
Email: IR@wesanahealth.com
Phone: 702-329-8038

Media Contacts:
Isadora Forman
Email: media@wesanahealth.com  
Phone: 917-653-4613


Primary Logo

Source: Wesana Health

2022 GlobeNewswire, Inc., source Press Releases

All news about WESANA HEALTH HOLDINGS INC.
06/08WESANA HEALTH CEO DANIEL CARCILLO TO : Re-Imagining Substance Abuse, Addiction, and Mental..
AQ
05/31Wesana Announces First Quarter 2022 Financial Results
AQ
05/31Wesana Health Holdings Inc. Announces Resignation of Chad Bronstein as Executive Chairm..
CI
05/30Wesana Health Holdings Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/10Wesana Health Outlines Accelerated Drug Development Pathway
AQ
05/10Wesana Health Holdings Outlines Accelerated Drug Development Pathway
CI
05/05Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its..
AQ
05/05Wesana Health Holdings Announces Review of Strategic Alternatives of its Clinics and Ot..
CI
05/02Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highligh..
AQ
05/02Wesana Health Holdings Inc. Reports Earnings Results for the Full Year Ended December 3..
CI
More news
Financials (USD)
Sales 2022 1,56 M - -
Net income 2022 -21,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,27x
Yield 2022 -
Capitalization 2,76 M 2,76 M -
Capi. / Sales 2022 1,77x
Capi. / Sales 2023 1,01x
Nbr of Employees -
Free-Float 99,1%
Chart WESANA HEALTH HOLDINGS INC.
Duration : Period :
Wesana Health Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,14 $
Average target price 3,09 $
Spread / Average Target 2 183%
EPS Revisions
Managers and Directors
Daniel Carcillo Chief Executive Officer & Director
Zed Wang Chief Financial Officer & Secretary
Chad Bronstein Executive Chairman
Mark Wingertzahn Chief Scientific Officer
Mitchell Kahn Director
Sector and Competitors
1st jan.Capi. (M$)
WESANA HEALTH HOLDINGS INC.-87.76%3
MODERNA, INC.-37.79%61 810
IQVIA HOLDINGS INC.-14.72%44 878
LONZA GROUP AG-26.39%43 629
SEAGEN INC.10.47%31 500
ALNYLAM PHARMACEUTICALS, INC.31.58%26 782